Enough with data collection, FDA needs diversity policies to boost representation in clinical trials: report

Home / Intelligence / Industry Publications / Enough with data collection, FDA needs diversity policies to boost representation in clinical trials: report

Trinity’s recent whitepaper, titled Diversity in Clinical Trials Participation: A Life Sciences Perspective, was featured in a recent article by Fierce Biotech.

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.